Table 1 Baseline characteristics of the study participants in the intent-to-treat (ITT) population
Characteristic | Envonalkib (N = 131) | Crizotinib (N = 133) |
|---|---|---|
Age (years) | ||
Mean ± SD | 53.4 ± 10.80 | 51.8 ± 10.83 |
Median (Q1, Q3) | 53.0 (46.0, 62.0) | 52.0 (46.0, 59.0) |
<65 | 106 (80.92) | 119 (89.47) |
≥65 | 25 (19.08) | 14 (10.53) |
Sex (male) | 68 (51.91) | 68 (51.13) |
ECOG | ||
0 | 30 (22.90) | 40 (30.08) |
1 | 101 (77.10) | 93 (69.92) |
Clinical stage | ||
IIIB | 9 (6.87) | 7 (5.26) |
IV | 122 (93.13) | 126 (94.74) |
Pathological type | ||
Adenocarcinoma | 124 (94.66) | 124 (93.23) |
Others | 7 (5.34) | 9 (6.77) |
Brain metastasis (IRC-assessed) | ||
Yes | 43 (32.83) | 45 (33.83) |
No | 88 (67.17) | 88 (66.17) |
Number of previous lines of chemotherapy | ||
0 | 98 (74.81) | 101 (75.93) |
1 | 33 (25.19) | 32 (24.06) |
Smoking history | ||
Never-smoker | 90 (68.70) | 84 (63.16) |
Ex-smoker | 41 (31.30) | 46 (34.59) |
Current smoker | 0 | 3 (2.26) |
